We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott Laboratories’ (ABT - Free Report) Established Pharmaceuticals Division (“EPD”) operates solely in emerging geographies, with leading positions in many of the largest and fastest-growing pharmaceutical markets (including India, China, and countries across Asia, Latin America and the Middle East) for branded generics in the world. Banking on the successful execution of the company’s branded generic operating model, EPD is well-positioned for sustained growth in these expanding pharmaceutical markets.
Per a report by Triodos Investment Management, growth in emerging markets may decelerate to approximately 3.7% in 2025, below the 4% average of the past decade, caused by the ongoing geopolitical developments and new tariffs.
However, Abbott’s EPD sales in the second quarter of 2025 increased 6.9% on a reported basis and 7.7% organically. More than half of its top 15 markets, now surpassing $1 billion in quarterly sales for the first time, posted double-digit gains. Abbott’s strategic focus on biosimilars further strengthens its prospects, with 10 regulatory approval submissions completed across emerging markets. Furthermore, Abbott continues to sustain its long track record of delivering strong growth, which includes a five-year CAGR for EPD of 8%.
Year to date, Abbott shares have reached roughly 16.8%, outpacing the broader Medical Product industry and the S&P 500 benchmark, which have improved about 3.5% and 7.7%, respectively. During this time, Abbott has also outpaced key peers such as Pfizer (PFE - Free Report) and Boston Scientific (BSX - Free Report) . While shares of PFE, a pharmaceutical corporation with a broad portfolio of drugs and vaccines, declined 8.6%, those of Boston Scientific, which also operates in the emerging markets, advanced 15.1%.
ABT YTD Price Comparison
Image Source: Zacks Investment Research
Major Tailwinds Driving ABT Stock
Robust Growth in Core Diagnostics: Abbott continues to expand its Diagnostics business, which accounted for 19.5% of the total revenues in the second quarter of 2025. The company is witnessing increased global demand for routine diagnostic (excluding COVID-19 testing sales). Strong demand for its respiratory disease tests for flu, strep throat, and RSV is fueling growth across various settings like hospitals, labs and pharmacies. Core Lab Diagnostics, excluding China, grew 8% in the quarter, with strong momentum in the United States, Europe and Latin America. Moreover, a $0.5 billion investment in Illinois and Texas facilities, as well as the upcoming launch of the Alinity system, target further expansion into the $1 billion molecular testing market.
Strong Momentum in Diabetes Care: Abbott’s Diabetes Care business is growing, driven by strong sales of its FreeStyle Libre CGM system, which is now the top choice for both Type 1 and Type 2 diabetic patients globally. Abbott also has two FDA-cleared over-the-counter CGMs, Lingo and Libre Rio, expanding access to over 6 million users worldwide.
In the second quarter, CGM sales exceeded $1.9 billion, up 19.6% organically, with U.S. Libre sales rising nearly 26%. The upcoming dual-analyte sensor with ketone monitoring is expected to further boost Abbott’s CGM leadership.
Steady 2025 Financial Guidance: Abbott expects full-year 2025 organic sales growth, excluding COVID-19 testing-related sales, to be in the range of 7.5-8.0%, or 6.0-7.0% when including COVID-19 testing-related sales. It projects full-year 2025 adjusted operating margin to be approximately 23.5% of sales. Full-year adjusted diluted earnings per share are expected to be in the range of $5.10-$5.20.
Estimates for ABT Heading South
The Zacks Consensus Estimate for Abbott’s 2025 sales and EPS implies a year-over-year improvement of 6.5% and 10.3%, respectively. However, the bottom-line estimates have shown downward movement in the past 30 days.
Image Source: Zacks Investment Research
ABT’s Downsides
Abbott continues to face a challenging business environment caused by trade tensions and the ongoing complex geopolitical situation globally. The deteriorating global economic environment continues to reduce demand for several MedTech products, leading to lower sales and product pricing, while increasing the cost of goods and operating expenses. In the second quarter, Abbott’s adjusted SG&A expenses increased 5.3% year over year.
In addition, the Chinese government’s adoption of volume-based procurement (VBP) policies is adversely impacting Abbott’s Diagnostics and EPD businesses in China. In Diagnostics, the VBP impact and delayed recovery in testing volumes are projected to be a $700 million headwind to full-year 2025 sales.
ABT Stock Valuation
With a forward five-year price-to-sales (P/S) of 4.92X, Abbott’s shares are trading at a discount compared with the industry average of 5.38X. It has a Value Score of C at present.
Image Source: Zacks Investment Research
Meanwhile, PFE’s five-year P/S of 1.21X is also lower than the industry average. But, BSX’s shares are trading at a premium (five-year P/S of 7.12X) compared with the industry average.
How to Play ABT Stock?
Abbott is demonstrating strong execution across key growth areas despite ongoing pricing pressures, increased costs, and regulatory headwinds, particularly in China. Its Diagnostics segment is expanding steadily, driven by robust global demand for routine and respiratory disease testing, alongside strategic investments and the upcoming launch of its Alinity system. Meanwhile, Diabetes Care continues to show strong momentum, with FreeStyle Libre leading globally and new OTC CGMs expanding access to over 6 million users. Backed by solid operational performance and a projected high single-digit organic sales growth (ex-COVID testing), Abbott remains on track to deliver consistent earnings and margin performance in 2025.
Abbott stock has excelled both the industry and its peers. Given its discounted valuation, the stock presents a solid investment option for investors.
Image: Bigstock
Abbott's EPD Growth Beats Market Trends: Here's How to Play the Stock
Key Takeaways
Abbott Laboratories’ (ABT - Free Report) Established Pharmaceuticals Division (“EPD”) operates solely in emerging geographies, with leading positions in many of the largest and fastest-growing pharmaceutical markets (including India, China, and countries across Asia, Latin America and the Middle East) for branded generics in the world. Banking on the successful execution of the company’s branded generic operating model, EPD is well-positioned for sustained growth in these expanding pharmaceutical markets.
Per a report by Triodos Investment Management, growth in emerging markets may decelerate to approximately 3.7% in 2025, below the 4% average of the past decade, caused by the ongoing geopolitical developments and new tariffs.
However, Abbott’s EPD sales in the second quarter of 2025 increased 6.9% on a reported basis and 7.7% organically. More than half of its top 15 markets, now surpassing $1 billion in quarterly sales for the first time, posted double-digit gains. Abbott’s strategic focus on biosimilars further strengthens its prospects, with 10 regulatory approval submissions completed across emerging markets. Furthermore, Abbott continues to sustain its long track record of delivering strong growth, which includes a five-year CAGR for EPD of 8%.
Year to date, Abbott shares have reached roughly 16.8%, outpacing the broader Medical Product industry and the S&P 500 benchmark, which have improved about 3.5% and 7.7%, respectively. During this time, Abbott has also outpaced key peers such as Pfizer (PFE - Free Report) and Boston Scientific (BSX - Free Report) . While shares of PFE, a pharmaceutical corporation with a broad portfolio of drugs and vaccines, declined 8.6%, those of Boston Scientific, which also operates in the emerging markets, advanced 15.1%.
ABT YTD Price Comparison
Image Source: Zacks Investment Research
Major Tailwinds Driving ABT Stock
Robust Growth in Core Diagnostics: Abbott continues to expand its Diagnostics business, which accounted for 19.5% of the total revenues in the second quarter of 2025. The company is witnessing increased global demand for routine diagnostic (excluding COVID-19 testing sales). Strong demand for its respiratory disease tests for flu, strep throat, and RSV is fueling growth across various settings like hospitals, labs and pharmacies. Core Lab Diagnostics, excluding China, grew 8% in the quarter, with strong momentum in the United States, Europe and Latin America. Moreover, a $0.5 billion investment in Illinois and Texas facilities, as well as the upcoming launch of the Alinity system, target further expansion into the $1 billion molecular testing market.
Strong Momentum in Diabetes Care: Abbott’s Diabetes Care business is growing, driven by strong sales of its FreeStyle Libre CGM system, which is now the top choice for both Type 1 and Type 2 diabetic patients globally. Abbott also has two FDA-cleared over-the-counter CGMs, Lingo and Libre Rio, expanding access to over 6 million users worldwide.
In the second quarter, CGM sales exceeded $1.9 billion, up 19.6% organically, with U.S. Libre sales rising nearly 26%. The upcoming dual-analyte sensor with ketone monitoring is expected to further boost Abbott’s CGM leadership.
Steady 2025 Financial Guidance: Abbott expects full-year 2025 organic sales growth, excluding COVID-19 testing-related sales, to be in the range of 7.5-8.0%, or 6.0-7.0% when including COVID-19 testing-related sales. It projects full-year 2025 adjusted operating margin to be approximately 23.5% of sales. Full-year adjusted diluted earnings per share are expected to be in the range of $5.10-$5.20.
Estimates for ABT Heading South
The Zacks Consensus Estimate for Abbott’s 2025 sales and EPS implies a year-over-year improvement of 6.5% and 10.3%, respectively. However, the bottom-line estimates have shown downward movement in the past 30 days.
Image Source: Zacks Investment Research
ABT’s Downsides
Abbott continues to face a challenging business environment caused by trade tensions and the ongoing complex geopolitical situation globally. The deteriorating global economic environment continues to reduce demand for several MedTech products, leading to lower sales and product pricing, while increasing the cost of goods and operating expenses. In the second quarter, Abbott’s adjusted SG&A expenses increased 5.3% year over year.
In addition, the Chinese government’s adoption of volume-based procurement (VBP) policies is adversely impacting Abbott’s Diagnostics and EPD businesses in China. In Diagnostics, the VBP impact and delayed recovery in testing volumes are projected to be a $700 million headwind to full-year 2025 sales.
ABT Stock Valuation
With a forward five-year price-to-sales (P/S) of 4.92X, Abbott’s shares are trading at a discount compared with the industry average of 5.38X. It has a Value Score of C at present.
Image Source: Zacks Investment Research
Meanwhile, PFE’s five-year P/S of 1.21X is also lower than the industry average. But, BSX’s shares are trading at a premium (five-year P/S of 7.12X) compared with the industry average.
How to Play ABT Stock?
Abbott is demonstrating strong execution across key growth areas despite ongoing pricing pressures, increased costs, and regulatory headwinds, particularly in China. Its Diagnostics segment is expanding steadily, driven by robust global demand for routine and respiratory disease testing, alongside strategic investments and the upcoming launch of its Alinity system. Meanwhile, Diabetes Care continues to show strong momentum, with FreeStyle Libre leading globally and new OTC CGMs expanding access to over 6 million users. Backed by solid operational performance and a projected high single-digit organic sales growth (ex-COVID testing), Abbott remains on track to deliver consistent earnings and margin performance in 2025.
Abbott stock has excelled both the industry and its peers. Given its discounted valuation, the stock presents a solid investment option for investors.
Abbott carries a Zacks Rank #3 (Hold) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.